Insider Buying: Anixa Biosciences (NASDAQ:ANIX) CEO Purchases 5,000 Shares

Anixa Biosciences Inc (NASDAQ:ANIX) CEO Amit Kumar purchased 5,000 shares of Anixa Biosciences stock in a transaction dated Monday, July 27th. The shares were acquired at an average cost of $3.44 per share, for a total transaction of $17,200.00. Following the transaction, the chief executive officer directly owned 652,000 shares of the company’s stock, valued at approximately $2,242,880. This represents a 0.77% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Amit Kumar also recently made the following trade(s):

• On Friday, July 24th, Amit Kumar purchased 3,000 shares of Anixa Biosciences stock. The shares were bought at an average cost of $3.73 per share, for a total transaction of $11,190.00.
• On Monday, July 20th, Amit Kumar bought 5,000 shares of Anixa Biosciences stock. The shares were purchased at an average price of $3.46 per share, with a total value of $17,300.00.
• On Monday, July 27th, Amit Kumar acquired 3,188 shares of Anixa Biosciences stock. The stock was purchased at an average price of $3.37 per share, for a total transaction of $10,743.56.
• On Friday, July 10th, Amit Kumar acquired 5,000 shares of Anixa Biosciences stock. The stock was bought at an average price of $3.04 per share, for a total transaction of $15,200.00.
• On Friday, June 12th, Amit Kumar bought 21,000 shares of Anixa Biosciences stock. The stock was acquired at an average cost of $2.50 per share, for a total transaction of $52,500.00.

Anixa Biosciences Stock Up 2.6%

ANIX traded up $0.09 during trading hours on Tuesday, hitting $3.55. 172,348 shares of the company’s stock were exchanged, compared to its average volume of 178,140. The stock’s 50-day moving average is $2.91 and its two-hundred day moving average is $2.92. The stock has a market cap of $120.78 million, a price-to-earnings ratio of -11.45 and a beta of 0.59. Anixa Biosciences Inc has a 1-year low of $2.32 and a 1-year high of $5.46.

Anixa Biosciences (NASDAQ:ANIX) last announced its earnings results on Wednesday, June 10th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.03. On average, equities research analysts anticipate that Anixa Biosciences Inc will post -0.31 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on ANIX. Wall Street Zen upgraded Anixa Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, June 20th. Weiss Ratings restated a “sell (e+)” rating on shares of Anixa Biosciences in a research note on Wednesday, June 17th. D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 target price on shares of Anixa Biosciences in a research note on Tuesday, June 30th. Citigroup reissued a “buy” rating on shares of Anixa Biosciences in a research report on Friday, June 12th. Finally, HC Wainwright reissued a “buy” rating on shares of Anixa Biosciences in a research note on Friday, June 12th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Anixa Biosciences presently has a consensus rating of “Moderate Buy” and an average price target of $8.50.

Institutional Trading of Anixa Biosciences

Several large investors have recently added to or reduced their stakes in the business. Citadel Advisors LLC boosted its position in Anixa Biosciences by 31.6% during the third quarter. Citadel Advisors LLC now owns 96,010 shares of the company’s stock valued at $317,000 after purchasing an additional 23,072 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Anixa Biosciences during the 4th quarter worth approximately $161,000. Jane Street Group LLC boosted its stake in shares of Anixa Biosciences by 37.2% in the second quarter. Jane Street Group LLC now owns 41,800 shares of the company’s stock valued at $138,000 after purchasing an additional 11,340 shares during the period. Prosperity Wealth Management Inc. increased its stake in Anixa Biosciences by 14.5% during the 3rd quarter. Prosperity Wealth Management Inc. now owns 41,800 shares of the company’s stock valued at $138,000 after buying an additional 5,300 shares during the period. Finally, OMERS ADMINISTRATION Corp bought a new position in shares of Anixa Biosciences in the 4th quarter worth about $95,000. 29.13% of the stock is currently owned by institutional investors.

About Anixa Biosciences

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.